This article has no abstract; the first 100 words appear below.

Severe hemophilia has changed from a debilitating disease to a condition that is compatible with normal life, provided that patients receive a diagnosis early and also receive prophylactic therapy.1 The disease burden is now related largely to the demanding infusions and the development of alloantibodies that can neutralize the effect of exogenously administered clotting factors (so-called inhibitors). Products with an extended half-life have reduced the burden of treatment. In patients with hemophilia B, therapeutic levels can be obtained with infusions every 2 weeks.2 Yet, the high costs of lifelong prophylactic therapy and the continuous bleeding risk that is due to . . .